AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Abundant Produce

0.027

0.000

Volume:- -

Turnover:150.33K

Market Cap:2.29M

PE:- -

High:0.027

Open:0.027

Low:0.027

Close:0.027

52wk High:0.027

52wk Low:0.027

Shares:84.85M

Float Shares:39.30M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Abbott Laboratories Says Late-Breaking Data Supports Safety, Efficacy of Ablation Catheters

MT Newswires Live

Abbott Laboratories' MedTech Business Sustains Momentum Amid Nutrition Weakness, UBS Says

MT Newswires Live

Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says

MT Newswires Live

US Equity Markets Rise as Geopolitical Tensions Ease

MT Newswires Live

Top Midday Decliners

MT Newswires Live

Top Premarket Decliners

MT Newswires Live

GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.55 to $5.80, vs. FactSet Est of $5.68

MT Newswires Live

Is Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum?

Simply Wall St.

Assessing Abbott Laboratories (ABT) Valuation After The CES 2026 Launch Of Libre Assist AI Tool

Simply Wall St.

Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns

Simply Wall St.

How Investors Are Reacting To Abbott (ABT) Expanding Lingo CGM And Nutrition Data For Metabolic Health

Simply Wall St.

Market Chatter: Abbott Laboratories Nearing Deal to Acquire Exact Sciences

MT Newswires Live

Abbott Laboratories (ABT): Evaluating Its Valuation Following Recent Share Price Pullback

Simply Wall St.

Can Abbott (ABT) Balance Medical Devices Growth Against Diagnostics Challenges in 2025?

Simply Wall St.

Abbott Labs' Business Momentum Intact Despite Mixed Q3, RBC Says

MT Newswires Live

ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook

stock_story_highlight

Abbott (ABT) Profit Margin Surge Challenges Bearish Narratives Despite Earnings Decline Forecast

Simply Wall St.

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live

GUIDANCE: (ABT) Abbott Laboratories Expects 2025 Adjusted EPS Range $5.12 to $5.18, vs. FactSet Est of $5.15

MT Newswires Live

S&P 500 Posts Weekly Drop Amid Trump's Latest Tariff Threat

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ABT.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ABT.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ABT.AU\",,,,,undefined,":{"symbol":"ABT.AU","market":"AU","secType":"STK","nameCN":"Abundant Produce","latestPrice":0.027,"timestamp":1770852163592,"preClose":0.027,"halted":3,"volume":0,"delay":0,"changeRate":0,"nameEN":"Abundant Produce","floatShares":39299635,"shares":84848333,"eps":0,"marketStatus":"Halted","change":0,"latestTime":"02-12 10:22:43 AEDT","open":0.027,"high":0.027,"low":0.027,"amount":150332.332916766,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1770872400000},"marketStatusCode":2,"adr":0,"exchange":"ASX","adjPreClose":0.027,"openAndCloseTimeList":[[1770850800000,1770872400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"ABT.AU\",,,,,undefined,":{"symbol":"ABT.AU","floatShares":39299635,"roa":"--","roe":"--","lyrEps":0,"shares":84848333,"dividePrice":0,"high":0.027,"amplitude":0,"preClose":0.027,"low":0.027,"week52Low":0.027,"pbRate":"--","week52High":0.027,"institutionHeld":0,"latestPrice":0.027,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":0.027},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ABT.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ABT.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ABT.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609597811","title":"Abbott Laboratories Says Late-Breaking Data Supports Safety, Efficacy of Ablation Catheters","url":"https://stock-news.laohu8.com/highlight/detail?id=2609597811","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609597811?lang=en_us&edition=fundamental","pubTime":"2026-02-06 23:18","pubTimestamp":1770391097,"startTime":"0","endTime":"0","summary":"Abbott Laboratories  said Friday clinical data from two late-breaking presentations demonstrated the safety and efficacy of its minimally invasive ablation catheters for treating atrial fibrillation.Data from the study showed the Volt pulsed field ablation system achieved an 84.2% freedom from documented rhythm recurrence at 12 months in patients with paroxysmal atrial fibrillation. In patients with persistent atrial fibrillation, nearly 68% remained free from an additional episode following treatment, according to the company.Abbott said the single-arm study also found fewer therapy applications per vein, a repeat ablation rate of less than 6%, and significant improvements in patient-reported quality of life scores.The company also reported new data from a trial evaluating its sensor-enabled TactiFlex duo ablation catheter in more complex atrial fibrillation cases.Six-month data showed an 81% freedom from documented rhythm recurrence in paroxysmal atrial fibrillation patients, along w","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0234572021.USD","LU1691799644.USD","LU1989763690.USD","LU1061106388.HKD","BK4592","LU1721429402.USD","LU0170899867.USD","LU0058720904.USD","LU2211815571.USD","LU2324357040.USD","SGXZ23171101.USD","BK4585","BK4588","LU2237957902.USD","LU2237957811.SGD","IE0002141913.USD","LU2089984988.USD","SG9999002232.USD","LU0289739699.SGD","IE00B4R5TH58.HKD","BK4082","ABT.AU","BK4581","LU2112291526.USD","LU1057294990.SGD","LU2133065610.SGD","IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0266013472.USD","ABT","BK4566","LU0114720955.EUR","LU0122379950.USD","IE0009355771.USD","LU2468319806.SGD","IE00BJJMRZ35.SGD","LU1721429741.USD","LU1989763427.SGD","LU0882574055.USD","LU1023059063.AUD","BK4504","LU1914381329.SGD","IE00BFTCPJ56.SGD","LU0868494617.USD","SG9999004303.SGD","BK4533","SGXZ41872573.SGD","BK4568","SG9999002224.SGD"],"gpt_icon":0},{"id":"2605000454","title":"Abbott Laboratories' MedTech Business Sustains Momentum Amid Nutrition Weakness, UBS Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2605000454","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605000454?lang=en_us&edition=fundamental","pubTime":"2026-01-24 04:15","pubTimestamp":1769199352,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  fourth-quarter results were weighed down by weakness in its Nutrition business, but the stock's pullback presents an opportunity, supported by resilient earnings and strong MedTech growth, UBS Securities said in a Thursday note.UBS noted that despite Abbott's organic sales growth, excluding COVID, slowing to 3.8% in the fourth quarter, it remains confident in management's 2026 organic growth guidance of 6.5% to 7.5%, citing underappreciated MedTech tailwinds.The brokerage highlighted a rebound in electrophysiology following the US Volt launch, potential upside from an upcoming large left atrial appendage closure trial, and strong demand for Libre continuous glucose monitoring products.While uncertainty remains in Nutrition, which accounts for about 20% of sales, UBS said MedTech strength and accelerating growth into 2026 support a more positive view on the stock.UBS maintained its buy rating with a price target of $158.Shares of Abbott Laboratories were down 1.3% ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0868494617.USD","LU0058720904.USD","IE00B4R5TH58.HKD","BK4592","LU2237957902.USD","LU2112291526.USD","LU1721429741.USD","SG9999002232.USD","LU0170899867.USD","IE00BJJMRZ35.SGD","LU1057294990.SGD","LU0882574055.USD","BK4566","BK4568","ABT","IE0002141913.USD","BK4082","BK4533","LU2324357040.USD","LU2211815571.USD","LU1061106388.HKD","IE00BFTCPJ56.SGD","LU2133065610.SGD","IE00B2B36J28.USD","LU1989763690.USD","LU0114720955.EUR","SG9999004303.SGD","LU2468319806.SGD","BK4585","LU2237957811.SGD","LU0266013472.USD","LU1691799644.USD","LU1989763427.SGD","BK4504","LU1023059063.AUD","LU2089984988.USD","LU1914381329.SGD","IE0009355771.USD","SG9999002224.SGD","SGXZ23171101.USD","BK4588","BK4581","SGXZ41872573.SGD","LU0234572021.USD","IE00BJT1NW94.SGD","LU0122379950.USD","LU1721429402.USD","LU0289739699.SGD","ABT.AU"],"gpt_icon":0},{"id":"2605340237","title":"Abbott Laboratories Expects H2 Growth Driven by Product Launches, Nutrition Recovery, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2605340237","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605340237?lang=en_us&edition=fundamental","pubTime":"2026-01-24 01:14","pubTimestamp":1769188469,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) expects growth to accelerate in the second half of 2026, supported by new product launches, recovering Nutrition and Diagnostics businesses and easier year-over-year comparis","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE0002141913.USD","LU0289739699.SGD","IE0009355771.USD","BK4566","IE00B2B36J28.USD","IE00BJJMRZ35.SGD","BK4581","LU0170899867.USD","LU0234572021.USD","BK4533","SGXZ23171101.USD","BK4588","BK4082","IE00BFTCPJ56.SGD","LU0266013472.USD","IE00BJT1NW94.SGD","BK4592","LU1989763690.USD","LU0122379950.USD","LU1023059063.AUD","LU0114720955.EUR","LU0882574055.USD","LU2112291526.USD","LU0058720904.USD","ABT","LU2133065610.SGD","SG9999002224.SGD","LU0868494617.USD","LU1989763427.SGD","LU1691799644.USD","BK4504","LU1057294990.SGD","LU2089984988.USD","LU2237957902.USD","LU1721429741.USD","BK4585","LU2468319806.SGD","SGXZ41872573.SGD","SG9999002232.USD","BK4568","LU2211815571.USD","LU2237957811.SGD","LU2324357040.USD","ABT.AU","SG9999004303.SGD","IE00B4R5TH58.HKD","LU1721429402.USD","LU1061106388.HKD","LU1914381329.SGD"],"gpt_icon":0},{"id":"2605417378","title":"US Equity Markets Rise as Geopolitical Tensions Ease","url":"https://stock-news.laohu8.com/highlight/detail?id=2605417378","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605417378?lang=en_us&edition=fundamental","pubTime":"2026-01-23 05:13","pubTimestamp":1769116420,"startTime":"0","endTime":"0","summary":"Major US equity indexes ended higher Thursday as the US dropped planned tariffs on Europe and backed off pressure involving Greenland.* The personal consumption expenditures price index increased 0.2% in November, matching expectations and pushing the annual inflation rate to 2.8% from 2.7%, the Bureau of Economic Analysis reported.* US jobless claims last week edged up by 1,000 to 200,000, below the 209,000 projected in a Bloomberg survey.* March West Texas Intermediate crude oil fell $1.26 to settle at $59.36 per barrel, while March Brent crude, the global benchmark, was last seen down $1.18 at $64.06.* Datadog  shares rose 6.4%, the second-biggest gain on the S&P 500, after Stifel upgraded the stock to buy from hold and lowered its price target to $160 from $205.* Abbott Laboratories  shares fell 10%, the largest drop on the S&P, after the company reported a Q1 earnings outlook below market expectations, and Q4 revenue missed expectations.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DJX","USAW.SI","NQmain","QQQE","DDM","SQQQ","PSQ","QYLG","USJW.SI","SPDN","VTI",".IXIC","QQQJ","SPLV","XDTE","SPYV","SPXS","QID","MYMmain","SPY","DXD","TQQQ",".DJI","ABT","QYLD","NVIW.SI","SPMO","MNQmain","EQR","SH","JEPQ","SDS",".SPX","SPXL","TSYW.SI","BMAY","ABT.AU","VOOV","DIA","IVOO","VOO","SPXU","QQQY","SDOW","IVV","QLD","DOG","DDOG"],"gpt_icon":1},{"id":"2605414867","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2605414867","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605414867?lang=en_us&edition=fundamental","pubTime":"2026-01-23 03:29","pubTimestamp":1769110181,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) reported a Q1 earnings outlook below market expectations on Thursday, and revenue in the preceding quarter lagged expectations.Shares of the healthcare company slumped 10% as","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABT.AU","BK4107","LU0882574055.USD","SGXZ23171101.USD","IE0002141913.USD","LU0114720955.EUR","LU2237957902.USD","BK4504","LU0868494617.USD","SG9999002224.SGD","LU2112291526.USD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU1721429402.USD","ABT","LU2211815571.USD","LU1023059063.AUD","MKC","IE00BJJMRZ35.SGD","LU1914381329.SGD","BK4212","BK7017","GB00B4LPDJ14.GBP","LU0742534661.SGD","LU0251131958.USD","LU1057294990.SGD","LU0122379950.USD","LU0048573561.USD","LU0058720904.USD","LU1989763690.USD","BK4568","LU1989763427.SGD","ORI.AU","LU0251142724.SGD","LU0266013472.USD","LU2404859667.USD","SGXZ41872573.SGD","BK4581","GB00B4QBRK32.GBP","BK4588","ORI","LU1691799644.USD","BK4592","LU1061106388.HKD","LU0170899867.USD","IE00BJT1NW94.SGD","LU0963586101.USD","LU0234572021.USD","LU2133065610.SGD","BK4533"],"gpt_icon":0},{"id":"2605499784","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2605499784","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605499784?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:06","pubTimestamp":1769087217,"startTime":"0","endTime":"0","summary":"McCormick  shares were down 6.1% in recent Thursday premarket activity after the company posted lower-than-expected fiscal Q4 adjusted earnings and issued fiscal 2026 non-GAAP earnings outlook that trailed analysts' estimates.Mobileye Global  stock was down 6% after the company posted lower fiscal Q4 adjusted net income and revenue.Abbott Laboratories  shares were down 5.6% after the company reported lower-than-expected Q4 net sales.Procter & Gamble  stock was down 1.4% after the company posted lower-than-expected fiscal Q2 net sales.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IE00BJT1NW94.SGD","LU2242652126.USD","LU2404859667.USD","BK4558","LU2552382132.HKD","LU1868836914.USD","LU0868494617.USD","LU0690374615.EUR","LU0690374961.EUR","LU1023059063.AUD","LU1721429402.USD","LU0882574055.USD","ABT.AU","BK4212","SG9999001440.SGD","PG","LU2404859741.USD","LU0234572021.USD","MBLY","SG9999014542.SGD","LU1868837300.USD","LU2242646821.SGD","BK4559","IE00BWXC8680.SGD","ABT","LU1066053197.SGD","LU0323591593.USD","LU2468319806.SGD","LU1057294990.SGD","MKC","SG9999014575.USD","IE00BLSP4239.USD","LU1066051498.USD","LU2089984988.USD","LU1929549753.HKD","BK4585","LU0289739699.SGD","LU0124676726.USD","BK4082","LU1691799644.USD","IE000M9KFDE8.USD","BK4157","LU2552382058.USD","BK4588","LU2211815571.USD","LU0114720955.EUR","LU0058720904.USD","BK4550","LU0096364046.USD","LU0048573561.USD"],"gpt_icon":0},{"id":"2605049662","title":"GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.55 to $5.80, vs. FactSet Est of $5.68","url":"https://stock-news.laohu8.com/highlight/detail?id=2605049662","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605049662?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:36","pubTimestamp":1769085398,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ABT) Abbott Laboratories Expects 2026 Adjusted EPS Range $5.55 to $5.80, vs. FactSet Est of $5.68","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABT","ABT.AU"],"gpt_icon":0},{"id":"2605611484","title":"Is Abbott Laboratories (ABT) Pricing Reflect Its Medical Device And Diagnostics Momentum?","url":"https://stock-news.laohu8.com/highlight/detail?id=2605611484","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605611484?lang=en_us&edition=fundamental","pubTime":"2026-01-21 22:32","pubTimestamp":1769005930,"startTime":"0","endTime":"0","summary":"If you are wondering whether Abbott Laboratories at around US$121 a share is offering fair value or a potential mispricing, you are in the right place.\nThe stock is modestly positive over 1 year with a 5.7% return, but has seen shorter term pullbacks with a 2.5% decline over 7 days and a 3.4% decline over 30 days, while the 3 and 5 year figures sit at 14.2% and 15.7% respectively.\nRecent headlines around Abbott Laboratories have focused on its position in medical devices and diagnostics, as...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-reflect-its-medical-devic","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-reflect-its-medical-devic","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0868494617.USD","LU1061106388.HKD","BK4581","BK4585","SG9999002232.USD","LU0266013472.USD","SGXZ23171101.USD","LU0170899867.USD","BK4533","LU2112291526.USD","BK4568","LU2211815571.USD","DCF","LU1057294990.SGD","LU2089984988.USD","LU1691799644.USD","ABT.AU","LU1914381329.SGD","IE00BJT1NW94.SGD","LU2237957902.USD","LU2324357040.USD","IE0002141913.USD","BK4566","LU2237957811.SGD","BK4504","LU1023059063.AUD","SG9999004303.SGD","IE00BJJMRZ35.SGD","LU0882574055.USD","LU2133065610.SGD","LU0122379950.USD","LU1989763690.USD","IE00BFTCPJ56.SGD","SGXZ41872573.SGD","SG9999002224.SGD","BK4592","LU2468319806.SGD","BK4082","IE00B2B36J28.USD","LU0058720904.USD","LU0114720955.EUR","LU1721429741.USD","BK4588","IE0009355771.USD","LU1989763427.SGD","IE00B4R5TH58.HKD","LU0234572021.USD","LU1721429402.USD","ABT","LU0289739699.SGD"],"gpt_icon":0},{"id":"2603584951","title":"Assessing Abbott Laboratories (ABT) Valuation After The CES 2026 Launch Of Libre Assist AI Tool","url":"https://stock-news.laohu8.com/highlight/detail?id=2603584951","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603584951?lang=en_us&edition=fundamental","pubTime":"2026-01-16 08:48","pubTimestamp":1768524483,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) is back in focus after unveiling Libre Assist, an AI driven feature within its Libre app at CES 2026. The new tool is aimed at helping U.S. diabetes patients anticipate food related glucose responses.\nSee our latest analysis for Abbott Laboratories.\nDespite the buzz around Libre Assist and interest in upcoming earnings and the proposed Exact Sciences deal, Abbott's recent share price has been relatively soft, with a 90 day share price return showing a 3.9% decline...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-laboratories-abt-valuation-after-the-ces-20","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/assessing-abbott-laboratories-abt-valuation-after-the-ces-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1691799644.USD","LU1057294990.SGD","IE00B4R5TH58.HKD","LU1914381329.SGD","LU2089984988.USD","LU2211815571.USD","SG9999004303.SGD","LU1989763690.USD","SG9999002232.USD","BK4585","LU1023059063.AUD","LU0882574055.USD","LU0289739699.SGD","LU1989763427.SGD","LU0122379950.USD","LU1721429402.USD","IE00BFTCPJ56.SGD","BK4504","BK4581","LU2112291526.USD","ABT","IE0009355771.USD","LU0170899867.USD","BK4533","LU2237957902.USD","SGXZ41872573.SGD","DCF","BK4566","LU0114720955.EUR","LU2324357040.USD","BK4588","LU2237957811.SGD","IE00BJJMRZ35.SGD","LU1061106388.HKD","IE00B2B36J28.USD","SGXZ23171101.USD","LU1721429741.USD","BK4568","ABT.AU","SG9999002224.SGD","BK4592","IE00BJT1NW94.SGD","LU0234572021.USD","LU0058720904.USD","IE0002141913.USD","BK4082","LU2468319806.SGD","LU0868494617.USD","LU0266013472.USD","LU2133065610.SGD"],"gpt_icon":0},{"id":"2601241384","title":"Is Abbott Laboratories (ABT) Pricing Look Attractive After Recent Steady Multi‑Year Returns","url":"https://stock-news.laohu8.com/highlight/detail?id=2601241384","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601241384?lang=en_us&edition=fundamental","pubTime":"2026-01-08 02:20","pubTimestamp":1767810016,"startTime":"0","endTime":"0","summary":"If you have been wondering whether Abbott Laboratories at around US$127.78 is offering fair value or a premium price, this breakdown is designed to give you a clear and structured view.\nThe stock has recorded returns of 1.6% over the last 7 days, 2.2% over the last 30 days, 2.9% year to date, 14.8% over 1 year, 19.0% over 3 years, and 28.5% over 5 years, which many investors will weigh against current pricing.\nRecent attention on Abbott has centered on how its broad healthcare portfolio and...","market":"us","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-look-attractive-after-rec","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/is-abbott-laboratories-abt-pricing-look-attractive-after-rec","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1914381329.SGD","BK4082","DCF","BK4533","BK4566","LU0114720955.EUR","SGXZ41872573.SGD","LU1721429741.USD","BK4585","LU0289739699.SGD","LU0868494617.USD","LU1989763427.SGD","LU1691799644.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","ABT.AU","LU2468319806.SGD","LU2211815571.USD","LU0170899867.USD","SGXZ23171101.USD","IE00B2B36J28.USD","LU2089984988.USD","IE00BFTCPJ56.SGD","LU0882574055.USD","LU1721429402.USD","LU1023059063.AUD","BK4568","IE0002141913.USD","LU2112291526.USD","LU2133065610.SGD","LU1057294990.SGD","LU0266013472.USD","LU0122379950.USD","BK4588","IE0009355771.USD","LU1061106388.HKD","LU2237957811.SGD","SG9999002232.USD","SG9999004303.SGD","LU2237957902.USD","LU1989763690.USD","LU2324357040.USD","ABT","BK4581","LU0234572021.USD","LU0058720904.USD","IE00B4R5TH58.HKD","SG9999002224.SGD","BK4504","BK4592"],"gpt_icon":0},{"id":"2590562789","title":"How Investors Are Reacting To Abbott (ABT) Expanding Lingo CGM And Nutrition Data For Metabolic Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2590562789","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590562789?lang=en_us&edition=fundamental","pubTime":"2025-12-11 12:50","pubTimestamp":1765428644,"startTime":"0","endTime":"0","summary":"In early December 2025, Abbott announced that its Lingo over-the-counter continuous glucose monitor became available for Android users, while new real-world data linked both Lingo and Ensure Max Protein shakes to improved glucose control and metabolic health, particularly in people with obesity.\nThis combination of broader device access and data-backed nutrition benefits underscores how Abbott is connecting its medical devices and nutrition portfolios to everyday health habits, potentially...","market":"nz","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/how-investors-are-reacting-to-abbott-abt-expanding-lingo-cgm","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/how-investors-are-reacting-to-abbott-abt-expanding-lingo-cgm","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4504","BK4533","LU0114720955.EUR","BK4211","LU0266013472.USD","SGXZ23171101.USD","LU0170899867.USD","LU1914381329.SGD","LU1989763427.SGD","IE00B4R5TH58.HKD","LU0289739699.SGD","LU1691799644.USD","LU0122379950.USD","BK4082","SG9999004303.SGD","BK4581","LU0058720904.USD","LU1057294990.SGD","LU2133065610.SGD","SG9999002224.SGD","IE00BJJMRZ35.SGD","LU2112291526.USD","LU2468319806.SGD","IE00BJT1NW94.SGD","BK4592","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","ABT","LU0234572021.USD","BK4568","LU0868494617.USD","LU2324357040.USD","LU1023059063.AUD","LU2089984988.USD","LU2237957811.SGD","SG9999002232.USD","LU0882574055.USD","IE0009355771.USD","IE0002141913.USD","LU2237957902.USD","SGXZ41872573.SGD","LU1061106388.HKD","LU2211815571.USD","BK4585","LU1721429402.USD","ISBC","ABT.AU","LU1721429741.USD","BK4566","LU1989763690.USD"],"gpt_icon":0},{"id":"2584204199","title":"Market Chatter: Abbott Laboratories Nearing Deal to Acquire Exact Sciences","url":"https://stock-news.laohu8.com/highlight/detail?id=2584204199","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584204199?lang=en_us&edition=fundamental","pubTime":"2025-11-20 02:49","pubTimestamp":1763578157,"startTime":"0","endTime":"0","summary":"Abbott Laboratories  is closing in on a deal to acquire medical testing company Exact Sciences , Bloomberg reported Wednesday, citing people familiar with the matter.Abbott and Exact Sciences didn't immediately reply to requests for comment from MT Newswires.Price: 126.48, Change: -3.52, Percent Change: -2.71","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4568","LU1023059063.AUD","IE00B4R5TH58.HKD","SG9999004303.SGD","BK4139","LU2211815571.USD","IE00BJJMRZ35.SGD","LU1721429741.USD","LU1721429402.USD","LU0266013472.USD","LU1691799644.USD","LU1057294990.SGD","LU1989763427.SGD","BK4566","LU2468319806.SGD","BK4504","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0058720904.USD","BK4581","LU0122379950.USD","LU1061106388.HKD","LU1914381329.SGD","LU2237957902.USD","EXAS","LU2089984988.USD","BK4533","IE00B2B36J28.USD","LU2112291526.USD","LU2237957811.SGD","ABT","LU1861559042.SGD","ABT.AU","IE0009355771.USD","LU1989763690.USD","BK4592","LU0170899867.USD","LU0289739699.SGD","LU0868494617.USD","LU2324357040.USD","LU2133065610.SGD","LU0882574055.USD","BK4082","SG9999002232.USD","SG9999002224.SGD","LU0114720955.EUR","LU0234572021.USD","IE00BJT1NW94.SGD","SGXZ23171101.USD","BK4548"],"gpt_icon":0},{"id":"2579352941","title":"Abbott Laboratories (ABT): Evaluating Its Valuation Following Recent Share Price Pullback","url":"https://stock-news.laohu8.com/highlight/detail?id=2579352941","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579352941?lang=en_us&edition=fundamental","pubTime":"2025-10-29 10:16","pubTimestamp":1761704177,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) shares have settled a bit lower over the past month, tracking a 5% dip as investors reassess healthcare stocks. The stock’s recent performance invites a closer look at its valuation and underlying trends.\nSee our latest analysis for Abbott Laboratories.\nAbbott Laboratories’ momentum has leveled off lately following a steady string of gains earlier this year, as investors weigh shifting healthcare trends and uncertainties around the sector. Over the past year,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-evaluating-its-valuation-following-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-laboratories-abt-evaluating-its-valuation-following-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4592","LU2237957902.USD","BK4504","BK4568","BK4581","LU0868494617.USD","SG9999002224.SGD","LU0122379950.USD","ABT","LU1989763690.USD","SG9999002232.USD","BK4588","LU0170899867.USD","LU1057294990.SGD","SGXZ23171101.USD","SG9999004303.SGD","DCF","LU2089984988.USD","IE00B4R5TH58.HKD","LU0234572021.USD","BK4585","LU0289739699.SGD","LU0882574055.USD","LU1721429741.USD","LU2237957811.SGD","IE0009355771.USD","LU1023059063.AUD","LU1721429402.USD","IE00BFTCPJ56.SGD","LU2112291526.USD","IE00BJJMRZ35.SGD","LU1914381329.SGD","LU0058720904.USD","IE0002141913.USD","LU1691799644.USD","LU2211815571.USD","IE00BJT1NW94.SGD","BK4566","LU2133065610.SGD","IE00B2B36J28.USD","LU0114720955.EUR","LU1989763427.SGD","ABT.AU","LU0266013472.USD","LU2468319806.SGD","BK4533","BK4082","LU1061106388.HKD","LU2324357040.USD"],"gpt_icon":0},{"id":"2576063127","title":"Can Abbott (ABT) Balance Medical Devices Growth Against Diagnostics Challenges in 2025?","url":"https://stock-news.laohu8.com/highlight/detail?id=2576063127","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576063127?lang=en_us&edition=fundamental","pubTime":"2025-10-17 21:42","pubTimestamp":1760708549,"startTime":"0","endTime":"0","summary":"Abbott Laboratories announced third-quarter 2025 earnings with sales of US$11.37 billion, up from US$10.64 billion a year prior, and net income essentially flat at US$1.64 billion year over year; the company also reaffirmed and narrowed its full-year adjusted EPS guidance to between US$5.12 and US$5.18.\nDespite strong growth in its medical devices segment, performance was mixed overall, as diagnostics revenue declined and management maintained rather than raised its full-year guidance,...","market":"hk","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/can-abbott-abt-balance-medical-devices-growth-against-diagno","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/can-abbott-abt-balance-medical-devices-growth-against-diagno","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SG9999004303.SGD","LU2324357040.USD","LU2237957811.SGD","LU2089984988.USD","LU2237957902.USD","LU1023059063.AUD","IE0002141913.USD","BK4533","SG9999002232.USD","LU0058720904.USD","LU0122379950.USD","ABT","IE00B2B36J28.USD","SG9999002224.SGD","LU1061106388.HKD","LU0114720955.EUR","LU0170899867.USD","BK4585","IE00BJJMRZ35.SGD","BK4568","BK4581","IE0009355771.USD","IE00BJT1NW94.SGD","BK4082","LU1914381329.SGD","LU0882574055.USD","SGXZ23171101.USD","LU2133065610.SGD","LU0289739699.SGD","LU1721429402.USD","LU1721429741.USD","LU1989763690.USD","LU1989763427.SGD","LU2468319806.SGD","LU2112291526.USD","BK4588","LU2211815571.USD","BK4592","BK4504","IE00B4R5TH58.HKD","LU0266013472.USD","LU1057294990.SGD","LU0234572021.USD","BK4566","IE00BFTCPJ56.SGD","LU0868494617.USD","LU1691799644.USD","ABT.AU"],"gpt_icon":0},{"id":"2575172392","title":"Abbott Labs' Business Momentum Intact Despite Mixed Q3, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2575172392","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575172392?lang=en_us&edition=fundamental","pubTime":"2025-10-16 23:31","pubTimestamp":1760628687,"startTime":"0","endTime":"0","summary":"Abbott Laboratories'  underlying business momentum is intact heading into 2026 despite mixed Q3 results due to transient factors, RBC Capital said in a note Wednesday.\"ABT is a high-quality MedTech company, and as dips create opportunity with transitory Q3 headwinds, we reiterate our Outperform rating and $147 PT,\" RBC saidAbbott reported Q3 sales of $11.37 billion, missing the FactSet-polled consensus of $11.39 billion. Adjusted earnings climbed to $1.30 per share from $1.21 a year earlier, in line with the Street's expectation.The company also narrowed its 2025 adjusted earnings guidance range to between $5.12 and $5.18 from $5.10 to $5.20 previously.RBC noted that looking ahead to 2026 \"management pointed to being comfortable\" with the current Street estimates of high-single-digit revenue growth and double-digit growth EPS, \"which are in-line with long-term sustainable growth targets for the company.\"The RBC analysts said they remain positive on Abbott because of strong revenue unde","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1057294990.SGD","LU1914381329.SGD","ABT","LU0868494617.USD","IE00B2B36J28.USD","BK4588","LU2133065610.SGD","LU0058720904.USD","LU0882574055.USD","LU2089984988.USD","LU2468319806.SGD","SG9999002224.SGD","SGXZ23171101.USD","ABT.AU","BK4082","LU2112291526.USD","BK4533","LU2324357040.USD","BK4592","BK4566","BK4585","BK4504","BK4581","LU0266013472.USD","LU1989763427.SGD","IE00BJJMRZ35.SGD","LU1721429402.USD","LU1061106388.HKD","LU2237957811.SGD","LU0234572021.USD","LU0114720955.EUR","LU1023059063.AUD","IE00BFTCPJ56.SGD","IE0002141913.USD","LU1721429741.USD","LU2211815571.USD","IE00B4R5TH58.HKD","LU0289739699.SGD","IE00BJT1NW94.SGD","LU0122379950.USD","SG9999002232.USD","BK4568","LU0170899867.USD","LU1691799644.USD","LU2237957902.USD","SG9999004303.SGD","LU1989763690.USD","IE0009355771.USD"],"gpt_icon":0},{"id":"2575719875","title":"ABT Q3 Deep Dive: Q3 Results in Line with Expectations, Product Pipeline and Market Dynamics Shape Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2575719875","media":"stock_story_highlight","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575719875?lang=en_us&edition=fundamental","pubTime":"2025-10-16 13:31","pubTimestamp":1760592660,"startTime":"0","endTime":"0","summary":"Healthcare product and device company Abbott Laboratories (NYSE:ABT) met Wall Street’s revenue expectations in Q3 CY2025, with sales up 6.9% year on year to $11.37 billion. Its non-GAAP profit of $1.30 per share was in line with analysts’ consensus estimates.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_story_highlight","url":"https://stockstory.org/us/stocks/nyse/abt/news/earnings-call/abt-q3-deep-dive-q3-results-in-line-with-expectations-product-pipeline-and-market-dynamics-shape-outlook","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stockstory.org/us/stocks/nyse/abt/news/earnings-call/abt-q3-deep-dive-q3-results-in-line-with-expectations-product-pipeline-and-market-dynamics-shape-outlook","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_story_highlight","symbols":["BK4574","IE0002141913.USD","ABT","LU0868494617.USD","BK4581","BK4533","LU1721429741.USD","BK4555","BK4585","LU2089984988.USD","LU1989763427.SGD","LU2112291526.USD","LU0882574055.USD","BK4568","BK4082","IE0009355771.USD","LU0114720955.EUR","LU1057294990.SGD","LU2237957811.SGD","SG9999002224.SGD","SG9999002232.USD","BK4504","IE00BFTCPJ56.SGD","LU0289739699.SGD","SG9999004303.SGD","LU0122379950.USD","SGXZ23171101.USD","IE00B2B36J28.USD","F","LU2237957902.USD","LU2133065610.SGD","LU2324357040.USD","IE00BJJMRZ35.SGD","IE00B4R5TH58.HKD","LU1721429402.USD","LU2211815571.USD","IE00BJT1NW94.SGD","LU1989763690.USD","BK4592","LU1061106388.HKD","BK4588","BK4566","LU2468319806.SGD","LU1691799644.USD","ABT.AU","LU0170899867.USD","LU1023059063.AUD","LU1914381329.SGD","LU0234572021.USD","LU0058720904.USD"],"gpt_icon":0},{"id":"2575791765","title":"Abbott (ABT) Profit Margin Surge Challenges Bearish Narratives Despite Earnings Decline Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2575791765","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575791765?lang=en_us&edition=fundamental","pubTime":"2025-10-16 12:42","pubTimestamp":1760589763,"startTime":"0","endTime":"0","summary":"Abbott Laboratories (ABT) posted net profit margins of 31.8%, more than doubling last year’s 14% margin. Earnings jumped 142% year-over-year, outpacing the company’s 18.1% annualized earnings growth over the past five years. Looking ahead, revenue is forecast to climb at 7% per year, trailing the broader US market’s 10% growth outlook, and consensus expects earnings to decline by an average of 7.1% annually through the next three years. The results present a mix of high profitability and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/company-cover/247483-main-header/1756216816685"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-abt-profit-margin-surge-challenges-bearish-narratives","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-abt/abbott-laboratories/news/abbott-abt-profit-margin-surge-challenges-bearish-narratives","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ABT.AU","ABT"],"gpt_icon":0},{"id":"2575755757","title":"Sector Update: Health Care Stocks Advance Late Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2575755757","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575755757?lang=en_us&edition=fundamental","pubTime":"2025-10-16 03:47","pubTimestamp":1760557639,"startTime":"0","endTime":"0","summary":"Health care stocks increased late Wednesday afternoon with the NYSE Health Care Index and the Health Care Select Sector SPDR Fund  each adding 0.3%.The iShares Biotechnology ETF  climbed 1.6%.In corporate news, Omeros  shares more than doubled after the company signed an asset purchase and license deal for its zaltenibart drug, under development to treat rare blood and kidney disorders, with Novo Nordisk  for up to $2.1 billion.Johnson & Johnson's  decision to spin off its orthopedics business into a standalone company called DePuy Synthes came as a surprise but should boost the company's growth in the longer term, Morgan Stanley said in a note. Morgan Stanley lifted its price target on Johnson & Johnson to $190 from $178 while maintaining its equal-weight rating. Johnson & Johnson shares added 0.3%.Abbott Laboratories  shares fell 2.5% after it reported Q3 net sales of $11.37 billion, up from $10.64 billion a year ago but below the FactSet consensus of $11.39 billion.Pfizer  Chief Exe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2471134796.USD","LU0289739699.SGD","XLV","NVO.AU","IE00B7SZLL34.SGD","LU2357305700.SGD","LU2089284900.SGD","LU1720051108.HKD","LU1674673691.USD","BK4592","LU0114720955.EUR","LU1023059063.AUD","OMER","LU0158827948.USD","LU1496350502.SGD","SG9999011175.SGD","LU0640476718.USD","BK4588","LU0912757837.SGD","LU1363072403.SGD","BK4550","ABT.AU","LU0456855351.SGD","BK4082","LU1989772923.USD","LU0203345920.USD","LU1162221912.USD","LU2505996681.GBP","NVO","IBB","IE0009355771.USD","LU0466842654.USD","BK4533","LU1221951129.SGD","SG9999001176.USD","LU2112291526.USD","LU2750360641.GBP","LU2750360997.AUD","LU2468319806.SGD","LU1221951046.USD","LU2023251221.USD","PFE.AU","JNJ","XBI","LU0306806265.USD","LU1883839398.USD","LABU","BK4585","ABT"],"gpt_icon":1},{"id":"2575778959","title":"GUIDANCE: (ABT) Abbott Laboratories Expects 2025 Adjusted EPS Range $5.12 to $5.18, vs. FactSet Est of $5.15","url":"https://stock-news.laohu8.com/highlight/detail?id=2575778959","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575778959?lang=en_us&edition=fundamental","pubTime":"2025-10-15 19:33","pubTimestamp":1760527981,"startTime":"0","endTime":"0","summary":"GUIDANCE: (ABT) Abbott Laboratories Expects 2025 Adjusted EPS Range $5.12 to $5.18, vs. FactSet Est of $5.15","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ABT","ABT.AU"],"gpt_icon":0},{"id":"2574010084","title":"S&P 500 Posts Weekly Drop Amid Trump's Latest Tariff Threat","url":"https://stock-news.laohu8.com/highlight/detail?id=2574010084","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2574010084?lang=en_us&edition=fundamental","pubTime":"2025-10-11 04:45","pubTimestamp":1760129154,"startTime":"0","endTime":"0","summary":"The Standard & Poor's 500 fell 2.4% this week amid a fresh round of tariff worries.The index ended Friday's session at 6,552.51 and is now down 2% for October. It's still solidly in positive territory","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IVV","SDOW","USAW.SI","TQQQ","NEE",".IXIC","ARE.AU","SQQQ","AXP.AU","QID","BAC","SH","TSYW.SI","HAL","USJW.SI","MNQmain","OEF",".DJI","DOG","NQmain","APA.AU","APA","BLK.AU","SDS","HAL.AU","ARE","DDM","VOO","DHI","ABT",".SPX","AXP","CSGP","OEX","SPXU","DXD","PEP","SSO","UPRO","MESmain","SPY","PSQ","ESmain","ABT.AU","MYMmain","DJX","SCHW","QLD","BLK"],"gpt_icon":1}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}]}}